Aspira Women's Health
Biotech firm, Aspira Women's Health Inc., pioneers diagnostic tests and treatments for gynecologic issues in Texas.
- 85
- Public company
- Austin, TX, USUnited States
Biotech firm, Aspira Women's Health Inc., pioneers diagnostic tests and treatments for gynecologic issues in Texas.
aspirawh.comCrawled Oct 14, 2026
The paper discusses methods to improve early-stage ovarian malignancy detection when CA-125 is not informative, using a multivariate index assay.
Aspira offers testing options and bio-analytical solutions intended to help physicians diagnose and treat conditions and improve outcomes for women.
Aspira Women's Health is dedicated to the discovery, development, and commercialization of AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer.
The company offers testing options and uses a data-driven approach to support patients and healthcare providers in gynecologic care.
Aspira Women's Health's Privacy Policy describes how it processes and uses personally identifying information collected through the website. It does not cover information collected through other websites or by Aspira Women's Health in other venues.
Aspira Women's Health maintains the website as a service to the Internet community. Access to and use of its information are subject to terms and conditions that Aspira Women's Health may revise at any time.
Aspira Women’s Health names **John Fraser** as interim CEO after a leadership transition. The appointment follows an unspecified change in executive leadership at the women’s health-focused company. Fraser steps in to oversee operations during the transition period.
Jun 2026Investing.com IndiaNews article
Aspira Women’s Health and Cleveland Clinic are expanding their partnership to develop AI-driven diagnostic tools for women’s health. The collaboration focuses on accelerating biomarker discovery and improving translational research capabilities. The goal is to enable scalable clinical validation of these innovations.
May 2026Cleveland ClinicNews article
Aspira Women’s Health is finalizing construction of its molecular laboratory in Q2 2026 to advance its **ENDOinform™** blood test for endometriosis. The AI-driven diagnostics company specializes in noninvasive gynecologic disease tools. The lab expansion supports development and future commercialization of its high-potential diagnostic product.
Apr 2026BioSpaceNews article
Aspira Women’s Health reports its third-quarter 2025 financial performance and strategic progress. The AI-driven bio-analytics company focuses on women’s health solutions, leveraging data-driven diagnostics and personalized health insights. The update highlights operational milestones and ongoing advancements in its core technology platform.
Nov 2025ACCESS NewswireNews article